BOSTON, Nov. 19 Scimitar Equity Research, Inc. issues areview on ART Advanced Research Technologies, Inc.(Toronto Stock Exchange: ARA) entitled: "Reversing the Trend by EnergizingOptix's Commercialization Strategy with a Higher Margin Opportunity and Salesleadership". The analyst research is available on Scimitar's website:www.scimitarequity.com.
ART Advanced Research Technologies Inc. is a leader in molecular imagingproducts for the healthcare and pharmaceutical industries. ART has developedproducts in medical imaging, medical diagnostics, disease research, and drugdiscovery with the goal of bringing new and better treatments to patientsfaster. The Optix(R) optical molecular imaging system, designed formonitoring physiological changes in living systems at the preclinical studyphases of new drugs, is distributed directly by ART in North America andEurope and is used by industry and academic leaders worldwide. TheSoftScan(R) optical breast imaging device is designed to improve the diagnosisand treatment of breast cancer. ART is commercializing the SoftScan opticalmedical imaging device via a global strategic alliance with GE Healthcare, aworld leader in mammography and imaging. Finally, the Fenestra(R) line ofmolecular imaging contrast products provide image enhancement for a wide rangeof preclinical Micro CT applications allowing scientists to see greater detailin their imaging studies, with potential extension into other major imagingmodalities. The distribution of the Fenestra line of imaging contrast agentsis made through GE Healthcare Bio-Science KK in Japan and is sold directly bythe Company in the rest of the world. ART's shares are listed on the TSXunder the ticker symbol ARA. For more information on ART, visit the websiteat www.art.ca .
Scimitar Equity Research, Inc. provides equity research of emerginghealthcare companies for the institutional and investment communities. Wecertify that all the views expressed in this review, accurately reflect ourpersonal views about ARA.TO (TSX) and its or their securities. No part of ourcompensation was, is, or will be, directly or indirectly, related to thespecific recommendations or views contained in this review and we will nothave any investment banking relationships or personal investment in anysponsored company. Investors are advised that this analysis and review isissued solely for informational purposes and is not to be construed as anoffer to sell or the solicitation of an offer to buy. Scimitar was paid forpreparing this review. This sponsored analysis and review does not haveregard to the specific investment objectives, financial situation and theinformation contained herein is based on sources that we believe to bereliable but is not guaranteed by us as being accurate and does not purport tobe a complete statement or summary of the available data. Any opinionsexpressed are statements of our own judgment as of the date of publication andare subject to change without notice. Please read all our importantdisclosures.CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559.1080 fax: (617) 559.1083 e-mail: email@example.com
SOURCE Scimitar Equity Research